secwatch.observer — SEC 8-K summary
======================================

Issuer:     Nordicus Partners Corp (NORD)
CIK:        0001011060
Form:       8-K
Filed at:   2024-05-16T23:59:59+00:00
Accession:  0001493152-24-020152
Event type: m_and_a
Sentiment:  positive
Materiality: 0.90
Item codes: 1.01, 2.01, 3.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Nordicus acquires 95% of Orocidin A/S for $38M in stock, enters periodontitis market
--------------------------------------------------------------------------------

- Acquired 525,597 Orocidin shares (95% stake) from 11 shareholders for 38M restricted common shares.
- Consideration valued at $38M in an all-stock transaction; closed May 13, 2024.
- Nordicus CEO Henrik Rouf and Director Henrik Keller join Orocidin's board of directors.
- Orocidin is a clinical-stage biopharma developing QR-01 for periodontitis; global market estimated >$1.3B by 2029.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1011060/000149315224020152/0001493152-24-020152-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1011060/000149315224020152/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001493152-24-020152

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer